Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.58 |
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2527213 | 0.98 | NR1H2 (0.57) | NR1H2NAMPTUSP2SMN1; SMN2DDB1 | |
| Ammonia Solution, Strong SCHEMBL21723640 | 0.98 | NR1H2 (0.57) | NR1H2NAMPTUSP2SMN1; SMN2DDB1 | |
| SCHEMBL20936863 | 0.86 | NR1H2 (0.74) | NR1H2NAMPTUSP2SMN1; SMN2DDB1 | |
| SCHEMBL12323778 | 0.86 | NR1H2 (0.74) | NR1H2NAMPTUSP2SMN1; SMN2DDB1 | |
| SCHEMBL29501587 | 0.86 | NR1H2 (0.74) | NR1H2NAMPTUSP2SMN1; SMN2DDB1 | |
| SCHEMBL3760597 | 0.86 | NR1H2 (0.74) | NR1H2NAMPTUSP2SMN1; SMN2DDB1 | |
| SCHEMBL321665 | 0.86 | NR1H2 (0.49) | NR1H2USP2SMN1; SMN2HPGDMEN1 | |
| SCHEMBL6197 | 0.86 | NR1H2 (0.49) | NR1H2USP2SMN1; SMN2HPGDMEN1 | |
| SCHEMBL346504 | 0.86 | NR1H2 (0.49) | NR1H2USP2SMN1; SMN2HPGDMEN1 | |
| SCHEMBL14743842 | 0.86 | NR1H2 (0.55) | NR1H2NAMPTUSP2SMN1; SMN2DDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 695 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026099594-A1 | THERAPEUTIC BIFUNCTIONAL AGENTS | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2026-05-15 | — | — | WO | disclosed |
| US-20260125367-A1 | CANCER TREATMENTS TARGETING CANCER STEM CELLS | REMEDY PLAN, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| WO-2026085629-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2026-04-30 | — | — | WO | disclosed |
| WO-2026087442-A1 | AMINO-IMIDAZOLE ANTIBACTERIAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2026-04-30 | — | — | WO | disclosed |
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-02 | — | — | US | disclosed |
| US-20260083708-A1 | IL-17 MODULATORS AND USES THEREOF | NNOCARE PHARMA INC (US) | 2026-03-26 | — | — | US | disclosed |
| US-12582661-B2 | Synthesis and application of class of respiratory syncytial virus inhibitors | Shanghai Ark Biopharmaceutical Co., Ltd. (CN) | 2026-03-24 | — | — | US | disclosed |
| EP-4682148-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Ireland Unlimited Company (IE) | 2026-01-21 | — | — | EP | disclosed |
| EP-4436667-B1 | PIPERAZINYLSULFONYLARYL COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | HOFFMANN LA ROCHE (CH) | 2026-01-21 | — | — | EP | disclosed |
| US-12528781-B2 | Heterocyclic GLP-1 agonists | GASHERBRUM BIO, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| WO-2005056003-A1 | DPP-IV INHIBITORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2005-06-23 | — | — | WO | disclosed |
| WO-2005056003-A1 | DPP-IV INHIBITORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2005-06-23 | — | — | WO | disclosed |
| WO-2005042540-A1 | THIENO-PYRIDINONE DERIVATIVES AS KINASE INHIBITORS | CELLTECH R & D LIMITED (GB) | 2005-05-12 | — | — | WO | disclosed |
| US-20050059702-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED CORPORATION (CA) | 2005-03-17 | — | — | US | disclosed |
| WO-2004093817-A2 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | ANORMED INC. (CA) | 2004-11-04 | — | — | WO | disclosed |
| WO-2004091518-A2 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2004-10-28 | — | — | WO | disclosed |
| US-20040209921-A1 | CXCR4 chemokine receptor binding comounds | ANORMED CORPORATION (CA) | 2004-10-21 | — | — | US | disclosed |
| EP-1456200-A1 | LACTAMS AS TACHYKININ ANTAGONISTS | Pfizer Limited (GB) | 2004-09-15 | — | — | EP | disclosed |
| US-20040132710-A1 | Lactams as tachkinin antagonists | PFIZER INC. | 2004-07-08 | — | — | US | disclosed |
| WO-2003051868-A1 | LACTAMS AS TACHYKININ ANTAGONISTS | PFIZER LIMITED (GB) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132710-A1 | Lactams as tachkinin antagonists | PROKR1, TACR2, TACR1 | NR1H2 1184/4885NAMPT 1880/4885USP2 3673/4885 |
| US-20260083708-A1 | IL-17 MODULATORS AND USES THEREOF | IL17A, IL2, IL23R | NR1H2 51/4885NAMPT 3713/4885USP2 4339/4885 |
| US-12528781-B2 | Heterocyclic GLP-1 agonists | GLP1R, GIPR, VIP | NR1H2 3555/4885NAMPT 2745/4885USP2 3639/4885 |
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | BCL2L2, BCL2A1, BCL2L1 | NR1H2 2155/4885NAMPT 4321/4885USP2 1066/4885 |
| US-20260125367-A1 | CANCER TREATMENTS TARGETING CANCER STEM CELLS | MCL1, MALT1, BCL6 | NR1H2 164/4885NAMPT 3339/4885USP2 2512/4885 |
| US-20040209921-A1 | CXCR4 chemokine receptor binding comounds | CXCR4, CXCR1, CXCR3 | NR1H2 105/4885NAMPT 2649/4885USP2 4210/4885 |
| US-20050059702-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | CXCR4, CXCR1, CCR5 | NR1H2 116/4885NAMPT 1200/4885USP2 3512/4885 |
| US-12582661-B2 | Synthesis and application of class of respiratory syncytial virus inhibitors | SNU13, TMPRSS11D, SPTBN1 | NR1H2 2971/4885NAMPT 1825/4885USP2 4536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.